Chemical cross-linking facilitates antigen uptake and presentation and provides improved protection from Mpox with a dual-antigen subunit vaccine

Abstract

Antigen uptake, processing, and presentation are crucial for the immune responses of protein-based vaccines. Herein, we introduced a reversible chemical cross-linking strategy to engineer protein antigens, which can be tracelessly removed upon antigen-presenting cell (APC) uptake and cellular reduction. The chemically cross-linked antigen proteins presented significantly enhanced uptake and epitope presentation by APC. We applied this strategy to monkeypox virus antigens A29L and A35R to construct dual-antigen subunit vaccines. Our results revealed that chemical cross-linking was robust enough to improve both proteins’ APC uptake and lymph node accumulation, with each protein being chemically cross-linked and administered separately. In vivo validation revealed that the chemical cross-linking of the two antigen proteins improved immune responses, with increases in antigen-specific antibody and live virus-neutralizing antibody production. Monkeypox virus challenge experiments revealed that dual-antigen vaccines prepared via the chemical cross-linking strategy mitigated tissue damage, reduced the virus load, and extended mouse survival, which proved that the chemical cross-linking strategy is valuable for protein-based subunit vaccine development. In consideration of the current threats from the monkeypox virus and potential future emerging pathogens, the chemical cross-linking strategy provide powerful tools.

Keywords

antigen uptake and presentation / chemical cross-linking / dual-antigen / monkeypox virus / subunit vaccine

References

[1] Fok-Moon L, Anthony T-R, Matthew ZT, et al. Monkeypox: disease epidemiology, host immunity and clinical interventions. Nat Rev Immunol. 2022; 22(10): 597-613.

[2] Yong H, Li M, Wei W, Monkeypox: epidemiology, pathogenesis, treatment and prevention. Signal Transduct Target Ther. 2022; 7(1): 373.

[3] Oriol M, Dimie O, Boghuma K T, et al. Monkeypox. Lancet. 2022; 401(10370): 60-74.

[4] WHO. Multi-country outbreak of mpox: External situation report#33. 2024. https://wwwwhoint/publications/m/item/multi-country-outbreak-of-mpox–external-situation-report-33–31-may-2024

[5] Onur K, Sara MM, Ingo D. Vaccinia virus: from crude smallpox vaccines to elaborate viral vector vaccine design. Biomedicines. 2021; 9(12): 1780.

[6] Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis. 2004; 4(1): 15-25.

[7] Sharon E F, Patricia L W, Heather H, Johannes B G, Paul C, Robert B B. Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals. Vaccine. 2014; 32(23): 2732-2739.

[8] Aysegul N, Elizabeth E Z. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther. 2010; 4: 71-79.

[9] Adesola Y-O, Mahmood D, Afolabi A, et al. Mpox (monkeypox) risk and mortality associated with HIV infection: a national case-control study in Nigeria. BMJ Glob Health. 2023; 8(11): e013126.

[10] Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Bio. 2022; 23(1): 3-20.

[11] Xu K, Gao P, Liu S, et al. Protective prototype—beta and delta-omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell. 2022; 185(13): 2265-2278.

[12] Chen L, Liu B, Sun P, et al. Severe acute respiratory syndrome coronavirus-2 spike protein nanogel as a pro-antigen strategy with enhanced protective immune responses. Small. 2020; 16(46): e2004237.

[13] Tang D, Liu XK, Lu J, et al. Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge. Front Immunol. 2023; 14: 1203410.

[14] Zeng JW, Li Y, Jiang LR, et al. Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge. Emerg Microbes Infec. 2023; 12(1): 2204151.

[15] Wang H, Yin P, Zheng TT, et al. Rational design of a ‘two-in-one’ immunogen DAM drives potent immune response against monkeypox virus. Nat Immunol. 2024; 25(2): 307-315.

[16] Fang ZH, Monteiro VS, Renauer PA, et al. Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens. Cell Res. 2023; 33(5): 407-410.

[17] Wang Y, Yang KW, Zhou H. Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: a rapid review. Int J Biol Macromol. 2023; 245: 125515.

[18] Sang Y, Zhang Z, Liu F, et al. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus. Signal Transduct Tar. 2023; 8(1): 172.

[19] Yang XT, Yang XD, Du SW, et al. A subunit vaccine candidate composed of Mpox virus A29L, M1R, A35R, and B6R elicits robust immune response in mice. Vaccines-Basel. 2023; 11(9): 1420.

[20] Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of monkeypox drugs. Drugs. 2022; 82(9): 957-963.

[21] Kandeel M, Morsy MA, Abd El-Lateef HM, et al. Efficacy of the modified vaccinia Ankara virus vaccine and the replication-competent vaccine ACAM2000 in monkeypox prevention. Int Immunopharmacol. 2023; 119: 110206.

[22] Jacob-Dolan C, Ty D, Hope D, et al. Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques. Sci Transl Med. 2024; 16(740): eadl4317.

[23] Su JR, Ng C, Lewis PW, Cano MV. Adverse events after vaccination among HIV-positive persons, 1990–2016. Plos One. 2018; 13(6): e0199229.

[24] Musiime V, Cook A, Bakeera-Kitaka S, et al. Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe. Pediatr Infect Dis J. 2013; 32(8): 856-862.

[25] Weiss RA. Natural and iatrogenic factors in human immunodeficiency virus transmission. Philos T R Soc B. 2001; 356(1410): 947-953.

[26] Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics. 2006; 118(2): E315-E322.

[27] Li MJ, Ren ZN, Wang YL, et al. Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus. Emerg Microbes Infec. 2023; 12(2): 2223669.

[28] Matho MH, Schlossman A, Meng XZ, et al. Structural and functional characterization of anti-A33 antibodies reveal a potent cross-species orthopoxviruses neutralizer. Plos Pathog. 2015; 11(9): e1005148.

[29] Pan HR, Li ZH, Wang J, et al. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: characterization, antigenicity and immunogenicity. Vaccine. 2017; 35(24): 3222-3231.

[30] He C, Yang JY, Hong WQ, et al. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat Commun. 2022; 13(1): 5459.

[31] Slon-Campos JL, Dejnirattisai W, Jagger BW, et al. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. Nat Immunol. 2019; 20(10): 1291-1298.

[32] Raccagni AR, Mancon A, Diotallevi S, et al. Monkeypox virus neutralizing antibodies at six months from Mpox infection: virologic factors associated with poor immunologic response. Viruses-Basel. 2024; 16(5): 681.

[33] Cohen BJ, Audet S, Andrews N, Beeler J, Red WWGMP. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine. 2007; 26(1): 59-66.

[34] Zhang NN, Li XF, Deng YQ, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020; 182(5): 1271-1283.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.